Prof Jason Carroll secures £2.3m Wellcome Trust Discovery Award
Prof Jason Carroll has received a Wellcome Trust Discovery Award, worth £2.3 million over six years, which enables his research group to pursue a new research project titled FOXA1: function and regulation of pioneer factors.
The award provides funding for established researchers to pursue bold and creative research ideas to deliver significant shifts in understanding that could improve human life, health and wellbeing.
FOXA1 is a transcription factor, a protein responsible for regulating how genes are expressed – that is involved in embryonic development, including the early differentiation of cells in specific organs of the body. Understanding and characterising FOXA1 thus has the potential to provide us with greater insight into the processes by which cancer-causing genetic errors can occur to co-opt these developmental processes.
Prof Jason Carroll and researchers in his group will explore the biochemical factors that regulate FOXA1 activity and the conditions that allow FOXA1 to function as a transcription factor. Their research hopes to uncover how FOXA1 induces cell-type specific regulatory events.
In particular, the Carroll Group seeks to establish how FOXA1 interacts with chromatin, the densely packed complex of DNA and proteins held within the cell nucleus that helps to protect DNA and regulate gene expression during cell division.
Prof Carroll said “We are excited about studying the fundamental processes of this highly unusual but important protein. The insight will help us understand how specialised master regulators like FOXA1 can change the genomic landscape and ultimately the fate of a cell, which is important given that FOXA1 is a major driver in breast and prostate cancer. We thank the Wellcome Trust for the opportunity to conduct this work.”
Related News
See all news-
New immune pathway offers treatment hope for childhood brain tumours
3rd February 2026
A newly discovered immune pathway could lead to gentler treatments for multiple childhood brain cancers, according to new research from our Gilbertson Group published today in Nature Genetics.
Find out more -
Targeting paused cells could improve chemotherapy for lung and ovarian cancers
3rd February 2026
New research published today in Nature Aging by scientists at the University of Cambridge sheds light on why some lung and ovarian cancers stop responding to chemotherapy, and how this resistance might one day be prevented.
Find out more -
Hot flush treatment has anti-breast cancer activity, study finds
5th January 2026
A drug mimicking the hormone progesterone has anti-cancer activity when used together with conventional anti-oestrogen treatment for women with breast cancer, a new Cambridge-led trial has found.
Find out more